IDH1 and central nervous system cancer: To determine how this molecular classification can assist in a more accurate diagnosis, we analyzed 8127 glioma samples (sequenced by F1 or F1CDx assays) and binned them into molecular subgroups based on IDH1/2 mutational status and codeletion of chromosomes 1p and 19q, as determined by F1/F1CDx (Figure 4).